[go: up one dir, main page]

WO1997030159A3 - Recombinant protein containing a c-terminal fragment of plasmodium msp-1 - Google Patents

Recombinant protein containing a c-terminal fragment of plasmodium msp-1 Download PDF

Info

Publication number
WO1997030159A3
WO1997030159A3 PCT/FR1997/000291 FR9700291W WO9730159A3 WO 1997030159 A3 WO1997030159 A3 WO 1997030159A3 FR 9700291 W FR9700291 W FR 9700291W WO 9730159 A3 WO9730159 A3 WO 9730159A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant protein
terminal fragment
protein containing
plasmodium
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1997/000291
Other languages
French (fr)
Other versions
WO1997030159A2 (en
Inventor
Shirley Longacre-Andre
Charles Roth
Faridabano Nato
John W Barnwell
Kamini Mendis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University Paris
Institut Pasteur
New York University NYU
Original Assignee
New York University Paris
Institut Pasteur
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University Paris, Institut Pasteur, New York University NYU filed Critical New York University Paris
Priority to AU18842/97A priority Critical patent/AU1884297A/en
Priority to KR1019980711022A priority patent/KR20000065265A/en
Priority to EP97905213A priority patent/EP0880589A2/en
Priority to CA002245727A priority patent/CA2245727A1/en
Priority to JP09529058A priority patent/JP2000506381A/en
Publication of WO1997030159A2 publication Critical patent/WO1997030159A2/en
Publication of WO1997030159A3 publication Critical patent/WO1997030159A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 42 kilodaltons (p42) of the surface protein 1 (protein MSP-1) of the merozoite form of a parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said p42 fragment being particularly deleted of its region II and, if necessary, also of its region III. Said recombinant protein is applicable to the production of vaccines against malaria.
PCT/FR1997/000291 1996-02-14 1997-02-14 Recombinant protein containing a c-terminal fragment of plasmodium msp-1 Ceased WO1997030159A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU18842/97A AU1884297A (en) 1996-02-14 1997-02-14 Recombinant protein containing a c-terminal fragment of plasmodium msp-1
KR1019980711022A KR20000065265A (en) 1996-02-14 1997-02-14 Recombinant Protein Containing C-terminal Fragment of Malaria Protozoal MSP-1
EP97905213A EP0880589A2 (en) 1996-02-14 1997-02-14 Recombinant protein containing a c-terminal fragment of plasmodium msp-1
CA002245727A CA2245727A1 (en) 1996-02-14 1997-02-14 Recombinant protein containing a c-terminal fragment of plasmodium msp-1
JP09529058A JP2000506381A (en) 1996-02-14 1997-02-14 Recombinant protein containing the C-terminal fragment of malaria parasite MSP-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR96/01821 1996-02-14
FR9601821A FR2744723A1 (en) 1996-02-14 1996-02-14 RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF AN MSP-1 PROTEIN FROM A PLASMODIUM INFECTIOUS TO MAN FOR THE PRODUCTION OF ANTI-MALARIA VACCINES

Publications (2)

Publication Number Publication Date
WO1997030159A2 WO1997030159A2 (en) 1997-08-21
WO1997030159A3 true WO1997030159A3 (en) 1997-12-31

Family

ID=9489187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/000291 Ceased WO1997030159A2 (en) 1996-02-14 1997-02-14 Recombinant protein containing a c-terminal fragment of plasmodium msp-1

Country Status (7)

Country Link
EP (1) EP0880589A2 (en)
JP (1) JP2000506381A (en)
KR (1) KR20000065265A (en)
AU (1) AU1884297A (en)
CA (1) CA2245727A1 (en)
FR (1) FR2744723A1 (en)
WO (1) WO1997030159A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026911A1 (en) * 1996-01-29 1997-07-31 Georgetown University Malaria vaccine based upon the addition of a msa1 peptide
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
CA2306796A1 (en) 1997-10-20 1999-04-29 Genzyme Transgenics Corporation Novel modified msp-1 nucleic acid sequences and methods for increasing mrna levels and protein expression in cell systems
US20030100106A1 (en) * 2000-02-08 2003-05-29 Chang Sandra P. Baculovirus produced Plasmodium falciparum vaccine
KR100373918B1 (en) * 2000-02-17 2003-02-26 주식회사 엘지생명과학 Enzyme immuno assay for malaria and reagent used therefor
AU2002343321A1 (en) 2001-01-26 2003-01-21 Walter Reed Army Institute Of Research Isolation and purification of plasmodium falciparum merozoite protein-142
US7595191B2 (en) 2001-01-26 2009-09-29 The United States Of America As Represented By The Secretary Of The Army Isolation and purification of P. falciparum merozoite protein-142 vaccine
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
AU2002306759B2 (en) * 2001-03-19 2007-05-31 Walter Reed Army Institute Of Research Recombinant P. vivax merozoite protein-1 p42 vaccine
WO2003084472A2 (en) 2002-04-01 2003-10-16 Walter Reed Army Institute Of Research Recombinant p. falciparum merozoite protein-142 vaccine
WO2015055772A1 (en) 2013-10-16 2015-04-23 Shirley Longacre Combination of plasmodium merozoite surface proteins msp4 and 1 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154454A1 (en) * 1984-02-22 1985-09-11 The Wellcome Foundation Limited Cloning of DNA for protozoal antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154454A1 (en) * 1984-02-22 1985-09-11 The Wellcome Foundation Limited Cloning of DNA for protozoal antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LONGACRE, S. ET AL.: "Plasmodium vivax merozoite surface protein 1 C-terminal recombinant proteins in baculovirus", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 64, no. 2, 1 January 1994 (1994-01-01), pages 191 - 205, XP000603954 *
LONGACRE, S.: "The Plasmodium cynomolgi merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 74, no. 1, 20 December 1995 (1995-12-20), pages 105 - 111, XP000603955 *

Also Published As

Publication number Publication date
AU1884297A (en) 1997-09-02
CA2245727A1 (en) 1997-08-21
JP2000506381A (en) 2000-05-30
WO1997030159A2 (en) 1997-08-21
FR2744723A1 (en) 1997-08-14
EP0880589A2 (en) 1998-12-02
KR20000065265A (en) 2000-11-06

Similar Documents

Publication Publication Date Title
WO1997030158A3 (en) Recombinant protein containing a c-terminal fragment of plasmodium msp-1
WO1997030159A3 (en) Recombinant protein containing a c-terminal fragment of plasmodium msp-1
PT82975A (en) Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein and of vaccine against the malaria
WO2005040206A8 (en) Glurp-msp3 fusion protein, immunogenic compositions and malarial vaccines containing it
WO2003016354A3 (en) Recombinant anti-plasmodium falciparum antibodies
WO1995007353A3 (en) Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
WO1996040766A3 (en) Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
WO2003060072A3 (en) Recombinant polypeptides
IL75788A (en) Peptide comprising a repeated sequence of four amino acids,which sequence occurs in plasmodium falciparum circumsporozoite protein
DK200201741A (en) Vaccine comprises chimeric malaria proteins derived from Plasmodium falciparum genetically coupled to Plasmodium falcinarum Merozoite surface protein 3
WO1995026982A3 (en) Malaria peptides
HUP0600028A2 (en) Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses
AU2992489A (en) Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
HUP9802238A2 (en) Modified polypeptides for enhanced immunogenicity
AU3763789A (en) Gene encoding 25 kDa surface protein of zygotes and ookinetes of plasmodium
NZ513549A (en) Malaria vaccine
WO1995008631A3 (en) Target antigens of transmission blocking antibodies for malaria parasites
GR3029665T3 (en) 16 kDa SURFACE PROTEIN OF -i(P. FALCIPARUM).
AU5718794A (en) Recombinant nucleic acid, polypeptide material coded thereby and transmission blocking vaccine based thereon for controlling the malaria parasite (plasmodium falciparum )
DE60235044D1 (en) REKOMBINANTES, 250 kDa LARGE ANTIGEN FROM SPOROZOITES / MEROZOITES OF EIMERIA MAXIMA CODING NUCLEIC ACIDS AND ITS USES
EP0392820A3 (en) Plasmodium circumsporozoite protein analogs lacking repeat sequences
WO2000063245A3 (en) Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant
AU1762092A (en) Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria
AU7163091A (en) Novel malarial sporozoite peptide antigens
GR3036312T3 (en) Polypeptides and dna encoding same, associated with human malaria parasites.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2245727

Country of ref document: CA

Ref document number: 2245727

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997905213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019980711022

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 97193042.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1997905213

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997905213

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980711022

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980711022

Country of ref document: KR